Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple claims regarding dosing limits and start doses (e.g., 'maximum for adults/seniors', 'starting 10–20 mg') are unsupported by the provided label excerpts. Several safety-risk phrasing statements are either unsupported (e.g., 'sign of liver failure') or overconfident (e.g., monitoring/dose adjustment framed as minimizing risk despite label stating no assurance). Peripheral artery disease risk reduction is also unsupported in the provided sections.
Category Scores
Accurate Statements
Lipitor belongs to the class of drugs called statins.
12.1 Mechanism of Action (HMG-CoA reductase inhibition) and references to 'other drugs in this class' / 'like other statins' (5.1), and drug interaction section (7).
Statins work by inhibiting the production of cholesterol in the liver.
12.1 Mechanism of Action (selective, competitive inhibitor of HMG-CoA reductase; cholesterol synthesis in the liver).
Rhabdomyolysis can lead to kidney damage.
5.1 Skeletal Muscle ('rhabdomyolysis with acute renal failure secondary to myoglobinuria').
Lipitor can interact with other medications.
7 Drug Interactions and 5.1 Skeletal Muscle (increased risk of myopathy/rhabdomyolysis with concurrent interacting agents); 17 Patient Counseling Information.
Interactions with other medications can increase the risk of adverse effects.
7 (increased risk of myopathy with concurrent administration of interacting agents) and 5.1 (increased risk of myopathy/rhabdomyolysis).
Lipitor can help reduce the risk of cardiovascular disease (supported as cardiovascular risk reduction).
1 Indications and Usage and 14 Clinical Studies (1.1 Prevention of Cardiovascular Disease) listing risk reductions (e.g., MI, stroke, revascularization/angina).
Lipitor can help reduce the risk of heart attacks.
14 Clinical Studies (1.1) ('Reduce the risk of myocardial infarction').
Lipitor can help reduce the risk of strokes.
14 Clinical Studies (1.1) ('Reduce the risk of stroke' and 'Reduce the risk of fatal and non-fatal stroke').
Lipitor can help lower cholesterol levels.
12.1 Mechanism of Action and 1 Indications and Usage (lipid-altering therapy; lipid reductions described in 12.1).
Lipitor can help lower LDL (bad) cholesterol.
12.1 Mechanism of Action (reduces LDL-C and related parameters).
Regular blood tests can help monitor liver function (and lipid panel monitoring is recommended).
17.2 Liver Enzymes (LFT timing and frequency) and 17 Patient Counseling Information (periodic testing of a fasting lipid panel).
Unsupported Statements
Lipitor is available in strengths including 10 mg, 20 mg, 40 mg, and 80 mg tablets.
Provided label excerpts include incidence of transaminase elevations by dose level (10/20/40/80 mg) but do not explicitly state tablet strengths/availability.
The maximum Lipitor dosage for seniors is typically 80 mg per day.
8.5 Geriatric Use advises caution/greater sensitivity; it does not state a 'maximum daily dose for seniors'.
The maximum dose of Lipitor for adults is 80 mg per day.
The provided excerpts do not state an adult maximum daily dose. (80 mg appears in a study comparison in 5.5, not as a dosing limit.)
The recommended starting dose for adults is 10 mg to 20 mg per day.
No starting dose range is provided in the supplied label excerpts.
Lipitor can help reduce the risk of peripheral artery disease.
No peripheral artery disease risk reduction indication is present in the provided label excerpts.
Liver damage can be a sign of liver failure.
The provided excerpts discuss liver enzyme abnormalities and contraindications/cautions, but do not mention 'liver failure' as a sign.
Kidney problems can be a sign of kidney failure.
The provided excerpt specifies 'acute renal failure' secondary to rhabdomyolysis; the broader 'kidney problems ... kidney failure' formulation is not explicitly stated as such.
Seniors may be more susceptible to side effects of Lipitor (as a general statement without uncertainty framing).
Label states no overall differences observed and notes greater sensitivity of some older adults cannot be ruled out; the claim is partially supported but not explicitly stated in a definitive way.
Contradictions
Low
AI Statement
The maximum Lipitor dosage may vary depending on individual factors such as kidney function, liver function, and other health conditions.
Label Reference
2.5 Dosage in Patients With Renal Impairment: 'Renal disease does not affect the plasma concentrations nor LDL-C reduction of LIPITOR; thus, dosage adjustment in patients with renal dysfunction is not necessary.'
Important Omissions
No evaluation/coverage of contraindications, boxed warnings, pregnancy/lactation risk, or pediatric use within the provided excerpt-based audit.
Importance:
High
No explicit label-supported administration/dosing regimen instructions were assessed (beyond starting/max-dose claims which were unsupported).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported dosing-limit/start-dose claims and overconfident risk-minimization phrasing could mislead prescribing/monitoring decisions; also an unsupported 'liver failure' sign statement may affect symptom interpretation. However, several core safety concepts (myopathy/rhabdomyolysis risk, drug interaction risk, and monitoring for liver enzymes) are aligned with label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Substantial unsupported dosing specificity (starting/max doses, 'maximum for seniors/adults') and unsupported/incorrect safety symptom interpretation ('sign of liver failure'); PAD risk reduction also unsupported in provided sections.
Suggested Improvement
Remove or rewrite unsupported dosing and PAD statements; align geriatric framing with 'greater sensitivity ... cannot be ruled out' and caution language. Replace 'liver failure' wording with label-supported liver enzyme abnormality language and monitoring recommendations. Ensure any monitoring/dose-adjustment statements do not claim risk is minimized when the label states 'there is no assurance' that monitoring will prevent severe myopathy.